Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Co.'s primary product candidate, Twyneo®, is a once-daily, non-antibiotic topical cream that it is developing for the treatment of acne vulgaris. Co.'s second branded product candidate is Epsolay®, a potential treatment for subtype II rosacea. Co.'s other branded product candidates are SGT-210, a potential treatment of palmoplantar keratoderma and non-melanoma skin cancer, and tapinarof and roflumilast, each a potential treatment of psoriasis and other dermatological indications. The SLGL stock yearly return is shown above.
The yearly return on the SLGL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SLGL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|